Sales Operations

"Too much is never enough." "All things in moderation.” There’s a big gap between those two axioms. And for field forces in life sciences, that gap often creates a big debate: How much data is too much? Your reps want to be informed. They want to know the latest insights when they’re out detailing doctors. Next best action suggestions help. But… if you give them too much information (and change ...

When the FDA approves existing drugs for new uses, it can disrupt the marketplace – and companies need to know how to adapt to the new sales environment. Glucagon-like peptide-1 (GLP-1) drugs are disrupting the MedTech marketplace right now. Previously used to treat type 2 diabetes, these drugs are the latest weapon in the battle against obesity, and they are so effective that the number of ...

The nature of sales operations in life sciences is changing rapidly as digital marketing becomes a core function for marketers. Sales representatives are still central to pharma sales, but they need to leverage data and analytics to tailor conversations and provide a personalized customer experience while helping healthcare professionals solve problems in a complex healthcare environment. Axtria ...

The COVID-19 pandemic has brought about many long-term changes to the pharma industry. One area that has seen effects directly caused by COVID-19 has been in sales operations design, management, and engagement with customers due to increased access restrictions of sales reps to physicians. COVID-19 has also accelerated institutional rethinking of the level and role of direct sales forces in the ...

This white paper looks at a simple but important research question – why do pharma companies have incentive compensation (IC) plans that cap their at-risk sales rep compensation? This paper provides reasons why such caps are not justified on both theoretical and empirical grounds, notes counterarguments to those who argue for IC caps, and offers two typical case studies that reveal both negative ...

Sales Crediting – a challenge most companies feel today with the increasing complexity of the market! Even more complex is the task of deciphering the downstream impact on incentive compensation and further impact on the sales reps’ motivation because of false crediting. With this whitepaper, unravel the means of actual and correct sales crediting and therefore, reduce pitfalls in incentive ...

Effective roster management has long been an overlooked topic in Pharma commercial operations. At any point in time, it is critical for the Sales Operations business processes to have access to the latest and distinct set of sales personnel that will need to be accounted for. All functions of commercial operations including sales force sizing, alignment management, call planning, and incentive ...

The question this white paper addresses is straightforward – will COVID-19 call for restructuring the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE model has been a go-to metric for sales response modeling, sales force optimization, and sales operations analyses for 20+ years. However, with the implications of COVID-19 on the global healthcare ...

The question this commentary asks is simply this - has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceutical companies to the point that they now may well stifle the very innovative environment needed by companies to meet the scientific demands and expectations of society? The answer to this question leads to understanding how ...